Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AISA-003
- Development stage
- Preclinical
- Lead developer
- Aisa Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
AISA-003 is an investigational small molecule transient receptor potential vanilloid 1 (TRPV1) antagonist being developed by Aisa Pharma. TRPV1 is a non-selective cation channel expressed on sensory nerves that is activated by heat, protons, and chemical stimuli, playing a key role in nociception and neurogenic inflammation. By blocking TRPV1-mediated signaling, AISA-003 aims to alleviate ocular surface pain (such as corneal-induced pain) and associated symptoms of ocular disorders without causing anesthetic effects. The drug is currently in early-stage development (Phase 0/Discovery) for the treatment of eye pain.
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on AISA-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AISA-003.